<DOC>
	<DOCNO>NCT01842854</DOCNO>
	<brief_summary>The purpose study analyze efficacy Galectin-3 biomarker Chagas Disease prognosis . This analysis do correlation plasmatic level molecule functional laboratory test .</brief_summary>
	<brief_title>Galectin-3 Biomarker Patients With Chagas Disease</brief_title>
	<detailed_description>Previous study indicate activate macrophage secrete Galectin-3 , molecule involve development fibrosis tissue rearrangement liver , kidney heart . Its plasmatic level increase patient acute decompensated heart failure . These observation suggest measure level Galectin-3 patient cardiac disease useful determine prognosis . To investigate role new biomarker Chagas Disease , study Chagas Disease population ( include patient indeterminate cardiac form disease ) . The assessment prognostic value Galectin-3 do comparison plasmatic level patient 's clinical evaluation , disease severity , inflammatory biomarkers cardiac function test . The patient include study must first sign write consent . They shall accompany specialized outpatient clinic Chagas disease - Hospital SÃ£o Rafael - Centro de Biotecnologia e Terapia Celular . They submit several test , include : - Collection Blood sample biochemical analysis ; - Electrocardiogram ; - Holter Electrocardiogram ; - Echocardiogram ; - Treadmill Test ; - X-Ray Imaging ; - Magnetic Resonance Imaging ; - Evaluation quality life application questionnaire ( SF 36 Minnesota Living With Heart Failure Questionnaire ) .</detailed_description>
	<mesh_term>Chagas Disease</mesh_term>
	<criteria>Chagas Disease diagnosis confirm 2 different serology Diagnosis indeterminate form cardiac form , without ventricular dysfunction . Significant valve disease define aortic stenosis gradient VE/Ao &gt; 50 mmHg Mitral stenosis valve area inferior 1,5 cm2 Severe moderate aortic and/or mitral regurgitation Chronic use immunosuppressive agent Dialysis treatment terminal renal failure Fever last 48 hour evidence systemic infection activity accord definition sepsis ACCP/SCCM ( American College o Chest Physicians/Society Critical Care Medicine ) Current abusive use alcohol illicit drug ( Based DSM IV ) Any comorbidities impact patient 's survival within next 2 year Liver disease activity Continuous use steroid treatment COPD Hematologic , neoplastic bone diseases Homeostasis disturbance Inflammatory diseases chronic infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Galectin-3</keyword>
	<keyword>Chagas disease</keyword>
	<keyword>Biomarkers</keyword>
</DOC>